These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31699321)

  • 21. A review on protein misfolding, aggregation and strategies to prevent related ailments.
    Shamsi TN; Athar T; Parveen R; Fatima S
    Int J Biol Macromol; 2017 Dec; 105(Pt 1):993-1000. PubMed ID: 28743576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complex proteinopathies and neurodegeneration: insights from the study of transmissible spongiform encephalopathies.
    Piccardo P; Asher DM
    Arq Neuropsiquiatr; 2018 Oct; 76(10):705-712. PubMed ID: 30427511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].
    Nagai Y
    Rinsho Shinkeigaku; 2009 Nov; 49(11):913-6. PubMed ID: 20030247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are comorbidities compatible with a molecular pathological classification of neurodegenerative diseases?
    Kovacs GG
    Curr Opin Neurol; 2019 Apr; 32(2):279-291. PubMed ID: 30672825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities.
    Visanji NP; Lang AE; Kovacs GG
    Transl Neurodegener; 2019; 8():28. PubMed ID: 31508228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transmissible amyloid.
    Tjernberg LO; Rising A; Johansson J; Jaudzems K; Westermark P
    J Intern Med; 2016 Aug; 280(2):153-63. PubMed ID: 27002185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteome-Scale Mapping of Perturbed Proteostasis in Living Cells.
    Lam I; Hallacli E; Khurana V
    Cold Spring Harb Perspect Biol; 2020 Feb; 12(2):. PubMed ID: 30910772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional amyloids: interrelationship with other amyloids and therapeutic assessment to treat neurodegenerative diseases.
    Som Chaudhury S; Das Mukhopadhyay C
    Int J Neurosci; 2018 May; 128(5):449-463. PubMed ID: 29076790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic strategies for targeting neurodegenerative protein misfolding disorders.
    Scannevin RH
    Curr Opin Chem Biol; 2018 Jun; 44():66-74. PubMed ID: 29902695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].
    Yoshida K; Higuchi K; Ikeda S
    Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antisense therapies for neurological diseases].
    Pulst SM
    Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Nucleolus as a Proteostasis Regulator.
    Amer-Sarsour F; Ashkenazi A
    Trends Cell Biol; 2019 Nov; 29(11):849-851. PubMed ID: 31473054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future.
    Lang AE
    Nat Med; 2010 Nov; 16(11):1223-6. PubMed ID: 21052078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurodegenerative lesions: seeding and spreading.
    Duyckaerts C
    Rev Neurol (Paris); 2013 Oct; 169(10):825-33. PubMed ID: 24035591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The neuropathological diagnosis of Alzheimer's disease.
    DeTure MA; Dickson DW
    Mol Neurodegener; 2019 Aug; 14(1):32. PubMed ID: 31375134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurodegenerative disorders: dysregulation of a carefully maintained balance?
    Swart C; Haylett W; Kinnear C; Johnson G; Bardien S; Loos B
    Exp Gerontol; 2014 Oct; 58():279-91. PubMed ID: 25219768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Proteinopathies--forms of neurodegenerative disorders with protein aggregation-based pathology].
    Shelkovnikova TA; Kulikova AA; Tsvetkov FO; Peters O; Bachurin SO; Bukhman VL; Ninkina NN
    Mol Biol (Mosk); 2012; 46(3):402-15. PubMed ID: 22888630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical implications of extracellular vesicles in neurodegenerative diseases.
    Vinaiphat A; Sze SK
    Expert Rev Mol Diagn; 2019 Sep; 19(9):813-824. PubMed ID: 31429341
    [No Abstract]   [Full Text] [Related]  

  • 39. A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies.
    Perani D; Iaccarino L; Lammertsma AA; Windhorst AD; Edison P; Boellaard R; Hansson O; Nordberg A; Jacobs AH;
    Alzheimers Dement; 2019 Aug; 15(8):1081-1103. PubMed ID: 31230910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications for neurodegenerative diseases.
    Victoria GS; Zurzolo C
    J Cell Biol; 2017 Sep; 216(9):2633-2644. PubMed ID: 28724527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.